Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
In this article:
Biogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer's treatment, citing steep side effects.
Advertisement
- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Research
- Personal Finance
- Videos
New on Yahoo
New on Yahoo
© 2024 All rights reserved.
Yahoo Finance
Yahoo FinanceSome parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.